Authors


Karrine D. Brade, PHARMD, BCPS AQ-ID, BCIDP

Latest:

So You Made the Decision to Implement Vancomycin AUC Dosing. Now What?

Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.


Mary Joyce B. Wingler PHARMD, BCIDP

Latest:

The ART of Implementing an Antiretroviral Stewardship Program

By addressing ART-related medication errors and increasing linkage to care, antiretroviral stewardship programs can improve management of inpatients with HIV.


Morgan Petronelli

Latest:

cUTI Roundtable: The Latest Therapeutic Developments

The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.


Monica Verduzco-Gutierrez, MD

Latest:

What We Know But Still Have to Learn About Long COVID

Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.


Logan Brock, PharmD

Latest:

Rethinking Fungal Blood Cultures in Sepsis Workups

Logan Brock, PharmD, presents data at MAD-ID, showing limited diagnostic yield from routine fungal cultures and delayed results compared with standard methods.


Caitlin Soto, PharmD, BCIDP

Latest:

A Long-Acting Injectable for the Treatment of Candida spp Infections

In the second installment of a 3-part series on long-acting injectables related to various infections, Caitlin Soto, PharmD, BCIDP, provides insights on using rezafungin for invasive candidiasis.


Andrew Handel, MD, FAAP

Latest:

'Tis the Season: Addressing Tick-Borne Illnesses

Andrew Handel, MD, discusses prevention, how to remove ticks, and the burden of Lyme disease in certain populations.


Laila M. Castellino, MD, FIDSA

Latest:

Rifaquizinone: A Novel Rifamycin-Quinolone Hybrid Antibiotic

Rifaquizinone is a dual-pharmacophore antibiotic combining rifamycin and a fluoroquinolone-like compound, showing strong bactericidal activity against resistant Staphylococcus aureus strains and biofilms, with promising results for treating prosthetic joint infections (PJI) but limited oral bioavailability.


Jane M. Carlton, PhD

Latest:

Decoding Malaria Parasites to Aid in Potential Treatments and Vaccines

The Johns Hopkins Malaria Research Institute’s work in this area is looking to find ways to identify, for the first time, every single gene in the genome of malaria parasites, which could lead to the development of new treatments or vaccines.



T. Sam Albanesi, MD, MA

Latest:

An Update on Lenacapavir

This new antiretroviral with a unique mechanism of action may be lifesaving for those with treatment-resistant HIV infection.


Jessica Malaty Rivera, MS

Latest:

mRNA COVID-19 Vaccines and Turbo Cancer: The Latest Myth That Won’t Disappear

The continuation of misinformation and disinformation being disseminated in the public is causing more public health communication issues as mistruths associate the vaccines with cancer.


Nisha Patel, PharmD, BCPS

Latest:

To Prophylax or not to Prophylax: Preventing CDI

Clinicians look at optimal approaches for trying to avoid Clostridioides difficile infection (CDI).


Eran Eden, PhD

Latest:

From Pathogen to Infectious Disease Diagnosis: Test Determines Between Bacterial and Viral Infections in 15 Minutes

MeMed CEO Eran Eden, PhD, discusses the MeMed BV test and how it can help make the distinction between the types of infections, aid in patient management, and reduce antimicrobial resistance.


Jenna Salay, BS

Latest:

What's New In 2024: From the CLSI Subcommittee on Antimicrobial Susceptibility Testing

The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.


Alison L. Blackman, PharmD, BCIDP

Latest:

So You Made the Decision to Implement Vancomycin AUC Dosing. Now What?

Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.


Sharmeen Roy, PharmD, BCPS

Latest:

AI as a Tool to Support Clinicians, Not Replace Them

Sharmeen Roy, PharmD, BCPS, on artificial intelligence (AI) in improving decision-making, reducing adverse drug events on National Adverse Drug Event Awareness Day, and upcoming research on pediatric dosing at the the Congress of the European Society of Clinical Microbiology and Infectious Diseases.


Ashley L. O’Leary, PHARMD, AAHIVP

Latest:

Outpatient Antimicrobial Stewardship: The Keys to Developing a Successful Program

This form of stewardship can reduce unnecessary antibiotic prescribing, reduce costs, and optimize patient outcomes.


Brandon Dionne, PharmD, BCPS-AQ ID, BCIDP, AAHIVP

Latest:

Going Viral on Social Media: Integrating Digital Tools into Pharmacy Rotations

In the latest Bench to Bedside column, 2 clinicians discuss the benefits of utilizing social media for learning.


Jesse S. Veisblatt, MD

Latest:

Bad Bugs, New Drugs: A Discussion of Selected New Therapeutics From IDWeek 2022

Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.


Joseph Zackular, PhD

Latest:

While Hospital-Acquired C difficile Cases Have Decreased, Community-Acquired Cases Have Risen

Joseph Zackular, PhD highlights targeting high-risk groups for vaccination and shares insights into the future of mRNA vaccine development for C diff.


Dana Holger, PharmD, MPH, AAHIVP

Latest:

Tricky Infusion Issues and Potential Solutions: OPAT Edition

Outpatient parenteral antimicrobial therapy (OPAT) offers benefits for patients as well as providing cost effectiveness; however, it is not without its challenges. Two clinicians provide insights on this modality.



Emily Jenkins PhD, DVM, BScHon

Latest:

Will the Melting Permafrost Uncover Vector Borne and Zoonotic Pathogens and Release Ancient Infectious Diseases?

With melting ice and the release of ancient viruses, there are concerns around the emergence of potentially unknown infectious diseases. Emily Jenkins PhD, DVM, BScHon, offers insights on “zombie viruses” and says polar bears might hold the key to understanding what lies ahead, and how a One Health approach may help in surveillance and prevention.



Brandon Garcia, PharmD, PGY2

Latest:

New Recommendations for Antibiotic Prophylaxis Prior to Dental Procedures

The American Dental Association (ADA) has updated patient profiles on who should be indicated for antibiotic prophylaxis.


Elizabeth Hastie, MD

Latest:

Long-Acting Injectable HIV Therapy: Addressing Adherence Challenges

Elizabeth Hastie, MD discussed the LATITUDE trial results, highlighting the need for wider access to this treatment, especially for those not virally suppressed, and could help shape future healthcare guidelines.


Sarah Green, PharmD, BCPS, BCIDP, AAHIVP

Latest:

Precision Dosing of To-Marrow: Linezolid Therapeutic Drug Monitoring

Emerging literature suggests therapeutic drug monitoring for this antimicrobial to minimize the risk for linezolid-associated toxicities while maintaining efficacy in select populations.


Bala Subramanian, PhD

Latest:

Bugworks' Antibiotic BWC0977 Targets Resistant Pathogens

Bala Subramanian, PhD, highlights how the novel antibiotic BWC0977, with its dual intravenous and oral formulation, is poised to transform the fight against antimicrobial resistance.


Theodore S. Rader IV, MD, MS

Latest:

Will We Ever See Oral Carbapenems for ESBL Urinary Tract Infections?

Recent issues surrounding the ADAPT-PO and SURE-2 trials place the spotlight on the difficulties developing oral carbapenem-based antibiotics and case their future into doubt.

© 2025 MJH Life Sciences

All rights reserved.